Free Trial
NASDAQ:KIDS

OrthoPediatrics Q3 2024 Earnings Report

OrthoPediatrics logo
$16.92 +0.11 (+0.65%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$16.72 -0.20 (-1.18%)
As of 06/3/2026 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OrthoPediatrics EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OrthoPediatrics Revenue Results

Actual Revenue
$54.57 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OrthoPediatrics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

OrthoPediatrics' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

OrthoPediatrics Earnings Headlines

SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required.tc pixel
See More OrthoPediatrics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OrthoPediatrics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OrthoPediatrics and other key companies, straight to your email.

About OrthoPediatrics

OrthoPediatrics (NASDAQ:KIDS), founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis. OrthoPediatrics also offers unique epiphysiodesis and guided growth devices designed to correct limb length discrepancies and angular deformities in growing children. These devices are supported by accompanying instrumentation that simplifies surgical technique and enhances procedural efficiency.

OrthoPediatrics markets its products through a direct sales organization in the United States and through distributors and regional offices in Europe, Latin America and the Asia-Pacific region. The company collaborates with leading pediatric orthopedic surgeons and academic institutions to advance clinical research, refine surgical protocols and expand its product offerings. Continuous investment in R&D underpins its strategy to fill gaps in pediatric care that are often overlooked by general orthopedic manufacturers.

Led by a management team with deep expertise in the orthopedic device industry, OrthoPediatrics emphasizes quality systems, regulatory compliance and physician education. The company’s global footprint and specialized focus on the pediatric segment position it as a growing participant in the niche market of children’s orthopedics, striving to improve clinical outcomes and quality of life for young patients worldwide.

View OrthoPediatrics Profile